T0	Outcomes 0 10	Evaluation
T1	Outcomes 152 179	pharmacokinetic interaction
T2	Outcomes 378 405	pharmacodynamic interaction
T3	Outcomes 484 506	antiplatelet activity.
T4	Outcomes 816 886	aspirin reactivity units (ARU, as measured by the VerifyNow ASA assay)
T5	Outcomes 1193 1343	antiplatelet activity of ASA, as assessed by ARU ratio relative to baseline in the VerifyNow ASA assay; suppression of serum thromboxane B(2) (TXB(2))
T6	Outcomes 1595 1607	achieved ARU
T7	Outcomes 1666 1697	(baseline) platelet aggregation
T8	Outcomes 1828 1851	of platelet aggregation
T9	Outcomes 1951 1971	reduced serum TXB(2)
T10	Outcomes 2017 2039	of serum TXB(2) levels
T11	Outcomes 2139 2153	well tolerated
T12	Outcomes 2166 2196	No pharmacodynamic interaction
T13	Outcomes 2257 2277	to platelet function